Statement: In total only one participant of the primary trial did not achieve Pathological Complete Response.
Primary_evidence: Outcome Measurement:    Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes.   Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy.   Time frame: Up to 30 days after last cycle of treatment Results 1:    Arm/Group Title: Cohort 1P (HER2 Positive)   Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 5   Measure Type: Count of Participants   Unit of Measure: Participants  4  80.0% Results 2:    Arm/Group Title: Cohort 1T (HER2 Positive)   Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 6   Measure Type: Count of Participants   Unit of Measure: Participants  6 100.0%